All treatments
Treatment
HyQvia 100 mg/ml solution for infusion for subcutaneous use clinical trials
2 indexed studies · 0 currently recruiting
- Ongoing, recruitingTherapeutic confirmatory (Phase III)
Influencing Progression of Airway Disease in Primary Antibody Deficiency
This study looks at people with primary antibody deficiency to see if a higher dose of immunoglobulin (Ig) replacement therapy can slow down lung problems. We'll compare lung changes over two years using scans and other health measures. This could help improve treatment for these conditions.
Netherlands - Ongoing, recruitingPhase II and Phase III (Integrated)
Multicenter, Prospective, Open-label, Randomized, Crossover Study to Evaluate Pharmacokinetics (PK), Safety, and Tolerability of TAK-881 in Primary Immunodeficiency Diseases (PIDD)
This study is looking at a new treatment called TAK-881 for people with primary immunodeficiency diseases (PIDD). Researchers want to understand how the body uses TAK-881, if it's safe, and if it helps prevent infections. It compares TAK-881 to an existing treatment, HyQvia.
For: Primary Immunodeficiency DiseasesSlovakia · Greece · Poland